Different Functional and Microstructural Changes Depending on Duration of Mild Cognitive Impairment in Parkinson Disease

N.-Y. Shin, Y.S. Shin, P.H. Lee, U. Yoon, S. Han, D.J. Kim and S.-K. Lee

AJNR Am J Neuroradiol 2016, 37 (5) 897-903
doi: https://doi.org/10.3174/ajnr.A4626
http://www.ajnr.org/content/37/5/897
Different Functional and Microstructural Changes Depending on Duration of Mild Cognitive Impairment in Parkinson Disease

N.-Y. Shin, Y.S. Shin, P.H. Lee, U. Yoon, S. Han, D.J. Kim, and S.-K. Lee

ABSTRACT

BACKGROUND AND PURPOSE: The higher cortical burden of Lewy body and Alzheimer disease–type pathology has been reported to be associated with a faster onset of cognitive impairment of Parkinson disease. So far, there has been a few studies only about the changes of gray matter volume depending on duration of cognitive impairment in Parkinson disease. Therefore, our aim was to evaluate the different patterns of structural and functional changes in Parkinson disease with mild cognitive impairment according to the duration of parkinsonism before mild cognitive impairment.

MATERIALS AND METHODS: Fifty-nine patients with Parkinson disease with mild cognitive impairment were classified into 2 groups on the basis of shorter (<1 year, n = 16) and longer (≥1 year, n = 43) durations of parkinsonism before mild cognitive impairment. Fifteen drug-naive patients with de novo Parkinson disease with intact cognition were included for comparison. Cortical thickness, Tract-Based Spatial Statistics, and seed-based resting-state functional connectivity analyses were performed. Age, sex, years of education, age at onset of parkinsonism, and levodopa-equivalent dose were included as covariates.

RESULTS: The group with shorter duration of parkinsonism before mild cognitive impairment showed decreased fractional anisotropy and increased mean and radial diffusivity values in the frontal areas compared with the group with longer duration of parkinsonism before mild cognitive impairment (corrected P < .05). The group with shorter duration of parkinsonism before mild cognitive impairment showed decreased resting-state functional connectivity in the default mode network area when the left or right posterior cingulate was used as a seed, and in the dorsolateral prefrontal areas when the left or right caudate was used as a seed (corrected P < .05). The group with longer duration of parkinsonism before mild cognitive impairment showed decreased resting-state functional connectivity mainly in the medial prefrontal cortex when the left or right posterior cingulate was used as a seed, and in the parieto-occipital areas when the left or right caudate was used as a seed (corrected P < .05). No differences in cortical thickness were found in all group contrasts.

CONCLUSIONS: Resting-state functional connectivity and WM alterations might be useful imaging biomarkers for identifying changes in patients with Parkinson disease with mild cognitive impairment according to the duration of parkinsonism before mild cognitive impairment. The functional and microstructural substrates may topographically differ depending on the rate of cognitive decline in these patients.

ABBREVIATIONS: AD = Alzheimer disease; DMN = default mode network; MCI = mild cognitive impairment; PCC = posterior cingulate cortex; PD = Parkinson disease; PD-IC = PD with intact cognition; PD-MCI = PD with mild cognitive impairment; PD-MCI-LD = PD-MCI with ≥1 year of parkinsonism prior to MCI; PD-MCI-SD = PD-MCI with <1 year of parkinsonism prior to MCI; RSFC = resting-state functional connectivity

Parkinson disease (PD) has been considered, until recently, primarily a motor disorder. It is now recognized that a substantial portion of patients with PD have measurable cognitive deficits ranging from mild cognitive impairment (PD-MCI) to dementia. Although the exact pathologic substrates for cognitive impairment in PD are still under debate, limbic and cortical Lewy body– and Alzheimer disease (AD)–type pathology have been suggested as the main contributors to dementia.
PD-MCI\textsuperscript{3–6} as well as PD with dementia.\textsuperscript{7–9} In terms of the rate of cognitive decline, a higher burden of these cortical pathologies\textsuperscript{7,10} has been reported associated with a faster onset of cognitive impairment in PD.

In contrast to pathologic studies, imaging studies are noninvasive and useful for discovering biomarkers in living humans. However, only a few structural imaging studies\textsuperscript{11,12} have been conducted thus far to define anatomic candidates influencing the rate of cognitive decline in PD. These studies have revealed atrophy of the posterior cingulate cortex (PCC)\textsuperscript{11} and inferior parietal and orbitofrontal areas\textsuperscript{12} in patients with PD with shorter durations of parkinsonism before dementia and MCI, compared with those with longer durations of parkinsonism. These regions show considerable overlap with the default mode network (DMN), which is well-known to be disrupted in patients with AD.\textsuperscript{13} Some authors have suggested that impairment of axonal transport causes accumulation of axonally transported substances followed by cortical Lewy body formation.\textsuperscript{14,15} In other words, alterations in WM, such as swelling and degeneration of the axonal projections, may precede cortical atrophy. Functional imaging is a more sensitive biomarker that detects earlier stages of disease than that of the corticostriatal loop, which is considered one of the primary areas of cognitive dysfunction in patients with PD.\textsuperscript{17}

\section*{MATERIALS AND METHODS}

\subsection*{Subjects}

This retrospective study was approved by the Yosei University Heath System institutional review board, and a waiver of informed consent was obtained. The patients were selected from a prospectively collected single-institution movement disorders and dementia outpatient clinic data base. From August 2011 to February 2014, consecutive patients with PD who underwent both MR imaging and neuropsychological tests within a 2-month interval were recruited. PD was diagnosed according to the clinical diagnostic criteria of the United Kingdom Parkinson’s Disease Society Brain Bank.\textsuperscript{20}

Assessment of parkinsonian motor symptoms was performed by using the Unified Parkinson’s Disease Rating Scale, Part III. Total medication dosages for PD were calculated in levodopa equivalents.\textsuperscript{21} The self-rating Beck Depression Inventory was used to assess depressive symptoms in patients with PD.\textsuperscript{22} Patients with focal brain lesions, diffuse white matter hyperintensities outside the normal range, or multiple lacunar infarcts in the basal ganglia on MR imaging were excluded. Patients with other neurodegenerative diseases and medical comorbidities that might account for cognitive dysfunction were also excluded. Only patients who displayed decreased dopamine transporter uptake in the posterior putamen on a $[^{18}F]$-N-3-fluoropropyl-2-$\beta$-carboxymethoxy-3-$\beta$-(4-iodophenyl) nortropane (FP-CIT) PET scan were included in this study, to ensure clinical diagnostic accuracy.

Information about memory problems or other subjective cognitive deficits was gathered by interviews with the patients or caregivers. The cognitive status diagnosis in patients with PD was assigned by consensus among 2 neurologists and 1 neuropsychologist on the basis of a neuropsychological battery and the physician-administered neurologic examination. The Seoul Neuropsychological Screening Battery was used to determine the cognitive status,\textsuperscript{23} and its details are described in On-line Appendix 1. According to the diagnostic criteria recommended by the Movement Disorder Society Task Force,\textsuperscript{24} PD-MCI was diagnosed when results of at least 2 tests for each of the attention, executive, memory, and visuospatial function domains, except for the language domain (level 2), or in 5 domains (level 1) were abnormal. Patients with PD-MCI were split into 2 groups by disease duration before MCI: PD-MCI with <1 year of parkinsonism before MCI (PD-MCI-SD) and PD-MCI with $\geq$1 year of parkinsonism before MCI (PD-MCI-LD). Drug-naive patients with de novo PD with intact cognition (PD-IC) were also included as control group.

\subsection*{Image Acquisition}

All scans were acquired by using a 3T scanner (Achieva; Philips Healthcare, Best, the Netherlands) with a 32-channel head coil. Head motion was minimized with restraining foam pads provided by the manufacturer.

\subsubsection*{Structural Image Acquisition.}

We used a 3D-T1-turbo field echo sequence with the following parameters: axial acquisition with FOV = 220 mm; voxel size = 0.98 $\times$ 0.98 $\times$ 1.2 mm$^3$; TE = 4.6 ms; TR = 9.6 ms; flip angle = 8$^\circ$; section gap = 0 mm; and total acquisition time = 5 minutes 29.3 seconds.

\subsubsection*{DTI Acquisition.}

A single-shot EPI acquisition was performed with the following parameters: FOV = 220 mm; voxel size = 1.72 $\times$ 1.72 $\times$ 2 mm$^3$; TE = $\sim$70 ms; TR = $\sim$8000 ms; flip angle = 90$^\circ$; section gap = 0 mm; NEX = 1; b factor = 600 s/mm$^2$; noncardiac gating; and 70 axial sections. We acquired diffusion-weighted images from 32 noncollinear, noncoplanar directions with a baseline image without diffusion-weighting. Total acquisition time was 5 minutes 44.6 seconds.

\subsubsection*{Resting-State fMRI Acquisition.}

We used a T2*-weighted single-shot EPI sequence. For each subject, 165 axial volume scans were obtained with the following parameters: FOV = 220 mm$^3$; voxel size = 2.75 $\times$ 2.75 $\times$ 4.5 mm$^3$; TE = 30 ms; TR = 2000 ms; and section number = 31 (interleaved). During each scan, subjects were instructed to rest and keep their eyes closed without moving, sleeping, or thinking about anything in particular for 5 minutes 38 seconds.

\subsection*{Image Analysis}

\subsubsection*{Cortical Thickness Analysis.}

Automated anatomic pipeline image processing steps were applied for cortical thickness measurement by using T1-weighted images. Details for measuring cortical
thickness are described in On-line Appendix 2. The localized regional differences of cortical thickness among groups were analyzed by applying ANCOVA, with age, sex, years of education, age at onset of parkinsonism, and levodopa-equivalent dose entered as covariates.

**Tract-Based Spatial Statistics Analysis.** DTI data preprocessing was performed by using the FMRIB Software Library (FSL; http://www.fmrib.ox.ac.uk/fsl) program. Details for Tract-Based Spatial Statistics (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/TBSS) analysis are described in On-line Appendix 3. In the ANCOVA analysis, age, sex, years of education, age at onset of parkinsonism, and levodopa-equivalent dose were included as covariates.

**Seed-Based RSFC Analysis.** Data were first preprocessed according to the Data Processing Assistant for Resting-State fMRI toolbox (http://www.restfmri.net) preprocessing pipeline implemented in Matlab (MathWorks, Natick, Massachusetts). Images were corrected for section timing, realigned, normalized by using the EPI template provided by SPM8 software (http://www.fil.ion.ucl.ac.uk/spm/software/spm8), and smoothed by using a 4-mm full width at half maximum Gaussian kernel. After normalization, to remove long-term drift and irrelevant oscillations in the signal, we detrended and bandpass filtered (0.01–0.08 Hz) data. Nuisance covariates, including head-motion parameters, global mean signals, WM signals, and CSF signals, were regressed out. To perform seed-based analysis, an Automated Anatomical Labeling template (http://www.gin.cnrs.fr/AAL) defined 90 seed ROIs. Among them, 4 ROI seeds were selected to study the association of cognition and resting-state functional networks in patients with PD. First, the bilateral PCC seeds were chosen to investigate alterations within the DMN. Second, the bilateral caudate seeds, which are known to be key subcortical structures in the cognitive corticostriatal loop, were also selected. RSFC from each ROI seed was estimated and used to configure a statistical map. Two sample t tests were performed on each pair of the group’s statistical images by using the SPM8 toolbox. The assumptions of unequal variance and independence among all groups were made on t tests. To exclude possible confounding factors, we covaried out age, sex, years of education, age at onset of parkinsonism, and levodopa-equivalent doses in the statistical test after normalization across 2 groups of interest by using the z score function in Matlab. The threshold for statistical analysis was set to corrected $P < .05$ by using the Monte Carlo simulations with custom software implemented in Matlab.25

**Correlation Analysis**

Two-tailed Pearson correlation analyses were performed to assess the relationship between the duration of parkinsonism before MCI and RSFCs, which showed remarkable differences between the PD-MCI-SD and PD-MCI-LD groups (left hippocampus and left medial frontal gyrus with the left PCC seed and left middle frontal gyrus with the left caudate seed). For each ROI, z values were extracted from correlation maps with a 4-mm radius sphere centered at the peak. Then, the correlation coefficients between the z values and the patients’ duration of parkinsonism before MCI were computed.

**Statistical Analysis**

Clinical characteristics and neuropsychological data were compared among the 3 groups. The Kolmogorov-Smirnov test was used to determine whether the data were normally distributed. Accordingly, data that had normal distribution are presented as means ± SDs, and quantitative variables were compared by using an ANOVA. Otherwise, for comparing quantitative values, data are presented as medians with ranges and the Kruskal-Wallis test was used. Qualitative data were analyzed by using the $\chi^2$ test or Fisher exact test when appropriate. Post hoc analysis was also performed by using a Bonferroni-corrected Student t test, Mann-Whitney U test, $\chi^2$ test, or Fisher exact test when appropriate with correction for multiple comparisons. Statistical analyses were performed by using SPSS, Version 19.0 (IBM, Armonk, New York), and 2-tailed $P < .05$ was considered significant.

**RESULTS**

**Demographic and Clinical Characteristics**

Among 239 patients with PD who underwent both MR imaging and neuropsychological tests, 59 patients with PD-MCI who met the inclusion criteria were analyzed in this study. Fifteen drug-naïve patients with de novo PD with intact cognition were also included for comparison. The demographic and clinical data of the patients are summarized in Table 1. The median duration of parkinsonism in the PD-MCI-SD group ($n = 16$) was 5 months and it was 25 months in the PD-MCI-LD group ($n = 43$). Patients in the PD-MCI-SD group had significantly older age at onset than those in the PD-MCI-LD group (68.5 ± 7.3 years versus 61.6 ± 9.0 years; $P = .016$). No significant differences were found in neuropsychological data between the 2 PD-MCI groups (On-line Table 1).

**Group Comparisons of Cortical Thickness**

No difference in cortical thickness was found among all groups.

**Group Comparisons of WM Alterations**

Compared with the de novo PD-IC group, the PD-MCI-SD group showed increased mean diffusivity in the bilateral anterior and superior corona radiata, genu and body of corpus callosum, right cingulum, and right superior longitudinal fasciculus and increased radial diffusivity in the right anterior and superior corona radiata, genu and body of the corpus callosum, right cingulum, and right superior longitudinal fasciculus (On-line Fig 1). The PD-MCI-LD group did not show significant WM alterations compared with the PD-IC group. In direct comparison between the PD-MCI-SD and PD-MCI-LD groups, the PD-MCI-SD group showed significantly decreased fractional anisotropy values in the right superior longitudinal fasciculus and corticospinal tract compared with the PD-MCI-LD group. More extensive changes were found in mean diffusivity and radial diffusivity values, showing a significant increase in the bilateral anterior and superior corona radiata, bilateral superior longitudinal fasciculus, genu and body of corpus callosum, right cingulum, and anterior and posterior limbs of the right internal capsule in the PD-MCI-SD group (Fig 1). No significant difference was found in axial diffusivity among groups.
Group Comparisons of RSFC by Using the PCC Seeds

Compared with the de novo PD-IC group, the PD-MCI-SD group showed decreased RSFC in the parahippocampal gyrus, dorsolateral prefrontal areas, temporal areas, and precuneus, whereas increased RSFC was seen in the inferior frontal areas, primary motor area, and occipital areas. The PD-MCI-LD group showed decreased RSFC in the medial frontal areas and middle cingulate cortex, while increased RSFC was seen mainly in the parietal and occipital areas, compared with the de novo PD-IC group. In direct comparison between the PD-MCI-SD and PD-MCI-LD groups, the PD-MCI-SD group showed decreased RSFC in the hippocampus, parietal areas, cuneus, and thalamus; on the contrary, the PD-MCI-LD group showed decreased RSFC in the medial and inferior frontal areas, primary motor area, cingulate cortex, inferior temporal area, and insula (Fig 2A, -B; On-line Fig 2 and On-line Table 2).

Group Comparison of RSFC by Using the Caudate Seeds

Compared with the de novo PD-IC group, the PD-MCI-SD group exhibited decreased RSFC in the putamen, temporal areas, precuneus, and insula and increased RSFC in the primary sensory motor areas. On the other hand, the PD-MCI-LD group showed decreased RSFC in the occipital area and thalamus and increased RSFC in the primary sensory motor areas, hippocampus/parahippocampal gyrus and other temporal areas, and the supramarginal gyri. In direct comparison between the PD-MCI-SD and PD-MCI-LD groups, the PD-MCI-SD group showed decreased RSFC in the putamen, globus pallidus, frontal and temporal areas, middle cingulate cortex, and insula, while the PD-MCI-LD group showed decreased RSFC mainly in the pari-
Correlation Analysis
The RSFC between the left caudate and left middle frontal gyrus (Montreal Neurological Institute coordinates \([-36, 33, 33]\)) was significantly correlated with the duration of parkinsonism before MCI \((r = 0.292, P = .025)\). RSFCs between the left PCC and left hippocampus (Montreal Neurological Institute coordinates \([-24, -36, -3]\)) and the left PCC and left medial frontal gyrus (Montreal Neurological Institute coordinates \([-6, 54, 24]\)) were not significantly correlated with the duration of parkinsonism before MCI (Fig 3).

DISCUSSION
The present study examined the different patterns of structural and functional changes in patients with PD-MCI according to the duration of parkinsonism before MCI. First, the PD-MCI-SD group showed decreased frontostriatal RSFC, which was correlated with the duration of parkinsonism before MCI, and impaired frontal WM integrity compared with the PD-MCI-LD group. Second, the pattern of RSFC was topographically different between the 2 groups. The PD-MCI-SD group showed decreased RSFC in the DMN, while the PD-MCI-LD group showed decreased RSFC in the medial frontal areas with the PCC seeds. Third, no difference was found in cortical thickness among all group contrasts.

As mentioned earlier, the PD-MCI-SD group showed not only decreased frontostriatal RSFC but also decreased fractional anisotropy values and increased mean diffusivity and radial diffusivity values in the frontal WM compared with the PD-MCI-LD group. These functional and microstructural differences might be attributable to both striatal\(^26,27\) and frontal\(^28,29\) pathologies. Recently, some pathologic studies have suggested striatal \(\beta\)-amyloid\(^26\) or \(\alpha\)-synuclein\(^27\) deposits as a primary substrate for subcortical dementia in PD. Moreover, a higher degree of amyloid deposits in the striatum was found in patients with dementia with Lewy bodies than in those with PD with dementia, suggesting the possible role of amyloid deposition in the acceleration of cognitive decline in \(\alpha\)-synuclein-related cognitive disorders.\(^30\) A previous imaging study also showed atrophy of the caudate nucleus and frontal cortex in patients with PD-MCI who subsequently converted to PD with dementia compared with those without conversion to PD with dementia.\(^31\) Furthermore, our results showed that frontostriatal RSFC had significant correlation with the duration of parkinsonism before MCI. In other words, patients with more disrupted RSFC among these areas had MCI with a shorter interval after the onset of motor symptoms. Although the effort to determine which substrate has a primary role in accelerat-
ing cognitive decline should be continued, functional or micro-
structural alterations in the frontostriatal circuit may be a useful
imaging biomarker for more rapid cognitive decline in patients
with PD-MCI.

Compared with the PD-MCI-LD group, the PD-MCI-SD
group also showed decreased RSFC in the DMN, including the
hippocampus and inferior parietal lobule when PCC was used as a
seed. Our results are in line with those in previous reports. Ac-
cording to previous imaging studies, patients with a shorter du-
ration of parkinsonism before cognitive impairment in PD with
dementia and PD-MCI had decreased GM volume in the PCC,1,1
and in the inferior parietal and orbitofrontal areas,1,2 respectively.
These areas substantially overlap with the DMN, which is suscep-
tible to decline in patients with AD.13 Moreover, a recent study
reported AD pattern atrophy involving the hippocampus and
temporal-parietal cortex as a predictor for 2-year future cognitive
decline in PD,32 suggesting that an AD imaging pattern is an im-
portant predictor for more rapid cognitive decline. Decreased
RSFC between the PCC and the hippocampus has been observed
in early AD and MCI.13,33 In AD, tauopathy involving the medial
temporal lobe, including the hippocampus, is considered a pos-
sible cause of the decreased connectivity.14 Although this finding is
less clear in PD,17,18 pathologic evidence has suggested that the
degree of Lewy body,15 Lewy neurite,16 β-amyloid, or neurofibril-
illary tangle deposit17 in the entorhinal cortex or hippocampus is
associated with cognitive dysfunction.

Most interesting, the PD-MCI-LD group had decreased RSFC
primarily in the medial frontal areas and cingulate when using the
PCC seeds compared with the PD-MCI-SD group. Braak et al18
reported sequential topographic extension of Lewy neurite and
Lewy body deposits in PD, with these areas showing substantial
overlap with the affected areas in stage 5, which is the first stage
of neocortical involvement. One pathologic study39 found that
among the patients who remained without dementia for a long
time, the patients who had longer disease durations until death
had more extensive Lewy body deposits, consistent with the PD
stage of Braak et al. These patients had no or a low AD pathology
burden. Therefore, decreased RSFC in these areas might be asso-
ciated with cortical PD pathology accumulated for longer disease
durations in the PD-MCI-LD group relative to the PD-MCI-SD
group. In addition, when the caudate seeds were used, the PD-
MCI-LD group showed decreased RSFC in mainly parieto-occip-
ital areas compared with the PD-MCI-SD group. These areas,
which are cognitive- and action-specific domains, have functional
connection with the caudate tail, while the caudate head has a
stronger functional connection with the prefrontal areas.40 Fur-
ther pathologic study is warranted to define different topographic
areas involved within the caudate between the 2 groups.

Our study has several limitations. First, our cohort was not
pathologically proved to have PD. Instead, we used dopamine
transporter imaging to reduce the possibility of misdiagnosis. Sec-
ond, the diagnosis of PD-MCI in this study did not fully satisfy the
level 2 criteria of the Movement Disorder Society Task Force
guideline for some patients.24 Therefore, the possibility of pa-
tients with false-positive diagnoses in the PD-MCI group cannot
be excluded. Third, although only the patients who underwent
both MR imaging and neuropsychological tests within a 2-month
interval were included, there were 1- to 50-day intervals in 21
patients in our cohort. While the cognitive state might not change
during this relatively short period, this range of intervals might
have affected the results. Fourth, because we used seed-based
RSFC analysis with only PCC and caudate seeds, the role of the
remaining areas for cognitive decline rates could have been
missed in patients with PD. Moreover, recent studies have sug-
gested that dorsal attention41 and frontoparietal networks41,42 are
associated with cognitive dysfunction in patients with PD-MCI.
Therefore, future study with a data-driven approach of the whole
brain should be conducted to consolidate our results and find
other relevant networks influencing the cognitive decline rate in
these patients. Fifth, it is still unclear what RSFC and DTI values
exactly represent in the brain. Therefore, caution is needed to
interpret our results until underlying pathologic evidence is elu-
cidated. Finally, this study is a cross-sectional one, so our findings
cannot be applied to predict the rate of development of cognitive
decline. A prospective study with regular follow-up with compre-
hensive neuropsychological testing is warranted. However, we
compared each PD-MCI group with the de novo PD-IC group,
and areas showing decreased RSFC in these comparisons were
similar to those in direct comparison between the 2 PD-MCI
groups. Therefore, we hope that our results can provide an a priori
hypothesis for future studies to define imaging biomarkers for the
cognitive decline rate in drug-naïve patients with de novo PD-IC.

CONCLUSIONS
Our results indicate that changes in RSFC and WM integrity in
PD-MCI according to the duration of parkinsonism before MCI
are more sensitive imaging biomarkers than cortical thickness.
We also found topographically different functional and micro-
structural substrates corresponding to the timing of MCI in
PD-MCI.

REFERENCES
dementia associated with Parkinson’s disease. Mov Disord 2007;22:
1689–707; quiz 837 Medline
2. Litvan I, Aarsland D, Adler CH, et al. MDS Task Force on mild cog-
nitive impairment in Parkinson’s disease: critical review of PD-
MCI. Mov Disord 2011;26:1814–24 CrossRef Medline
3. Adler CH, Cavinnes JN, Sabbagh MN, et al. Heterogeneous neuro-
pathological findings in Parkinson’s disease with mild cognitive
4. Jellinger KA. Neuropathology in Parkinson’s disease with mild cog-
nitive impairment. Acta Neuropathol 2010;120:829–30; author reply
31 CrossRef Medline
proteins, and cognitive performance, in early and untreated Par-
kinson’s disease: the Norwegian ParkWest study. J Neurol Neuro-
surg Psychiatry 2010;81:1080–86 CrossRef Medline
6. Montine TJ, Shi M, Quinn JF, et al. CSF β(42) and tau in Parkinson’s
disease with cognitive impairment. Mov Disord 2010;25:2682–85
CrossRef Medline
markers in Parkinson’s disease: a prospective longitudinal study.
Parkinsonism Relat Disord 2013;19:717–24 CrossRef Medline
correlates of cerebrospinal markers of Alzheimer–pathology in Par-
kinson’s disease and related dementia. Parkinsonism Relat Disord
2012;18:941–47 CrossRef Medline
34. Smith AD. Imaging the progression of Alzheimer pathology through the brain. Proc Natl Acad Sci USA 2002;99:4135–37 Medline